Tmunity
Acquired
Next-generation T-cell therapies for cancer.
- Headquarters
- Philadelphia, Pennsylvania
- Employees
- 1–10
- Founded
- 2015
- Business Model
- B2B
- Website
- tmunity.com
- Total Funding
- $185.0M
- Last Round
- $75.0M Venture RoundDec 2022
About
Tmunity Therapeutics developed next-generation engineered T-cell therapies (CAR-T and TCR-T) for solid tumors and hematologic malignancies in oncology. The company collaborated with biopharma partners and clinical centers before being acquired by Kite, a Gilead Company.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free Account